# Fulvestrant

## Faslodex inj 250mg/5mL

| TAH Drug Code      | [IFAS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFAS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer， metastatic， breast cancer， advanced or metastatic (second-line endocrine-based combination therapy)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | 500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections， one in each buttock， on Days 1， 15， 29， and once monthly thereafter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Central nervous system: Fatigue (8% to 29%)， headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%)， diarrhea (19%)， constipation (5% to 16%)， stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis， upper respiratory infection， urinary tract infection， influenza， bronchitis， rhinitis， conjunctivitis， pneumonia， sinusitis， cystitis， oral herpes， respiratory tract infection) Local: Pain at injection site (12%; including neuralgia， peripheral neuropathy， sciatica) 1% to 10%: Dermatologic: Alopecia (6%)， skin rash (6%)， xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%)， anorexia (6%)， vomiting (6%)， dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%)， leukopenia (5%; grade 3: 1%; grade 4: 1%)， neutropenia (4%; grade 3: 1%)， febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%)， arthralgia (8%)， back pain (8%)， limb pain (7%)， musculoskeletal pain (6%)， weakness (5% to 6%) Ophthalmic: Blurred vision (2%)， dry eye syndrome (2%)， increased lacrimation (1%) Respiratory: Cough (5%)， dyspnea (4%)， epistaxis (2%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/fulvestrant-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

